Abstract Library

#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ćwikla J

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,

Keywords: NENs, PRRT, Hindgut, CUP,

#1865 Evolution of Gastroenteropancreatic Neuroendocrine Tumors – Experiene of a Romanian Endocrine Clinic

Introduction: GEP-NETs (gastroenteropancreatic neuroendocrine tumors) are a heterogenous group of tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Poiana C

Authors: Baciu I, Galoiu S, Trifanescu R, Capatina C, Dumitrascu A,

Keywords: GEP-NETs,

#754 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Streptozocin-based chemotherapies are widely used in pancreatic NEN. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Mueller D, Krug S, Majumder M, Gress T, Rinke A,

Keywords: NEN, DTIC, MGMT,

#738 Interferon Alpha in the Management of Metastatic Neuroendocrine Tumors: A Retrospective Study in 37 Patients

Introduction: Interferon alpha (IFNα) has not been popular due to perceived lack of efficacy and toxicity profile. Current molecular targeted therapies demonstrate only modest anti-tumor effect with not insignificant toxicity.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: MIRVIS E

Authors: Mirvis E, Garcia-Hernandez J, Mandair D, Cheung V, Toumpanakis C,

Keywords: Interferon,

#534 Effect of Dacarbazine Chemotherapy in Well-Differentiated Neuroendocrine Tumors

Introduction: Despite encouraging results of streptozocin combinations in patients with metastatic endocrine pancreatic tumors, this treatment modality consists of a five-day cycle and can cause renal insufficiency. Dacarbazine (DTIC) (650mg/m2 every four weeks) can easily be applied in an outpatient setting, but data on efficacy are limited.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Müller D, Rinke A, Gress T,

Keywords: neuroendocrine tumor, chemotherapy, dacarbazine,